Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Community demand for temporary halt to Gilead DISCOVER study

A group of U.S., Canadian, and European community advocates and HIV NGO workers have written a letter exrpesing "deep dismay" that Gilead Sciences have proceeded with the DISCOVER trial PrEP"without engaging stakeholders in a substantial or meaningful way.". DISCOVER will compared Gilead's new comination pill, Descovy against Truvada as PrEP. In 2007, the HIV/AIDS field adopted Good Participatory Practice (GPP), a formal set of guidelines approved by UNAIDS for stakeholder engagement in HIV prevention clinical trials. "It is astonishing," says the letter, "that Gilead has failed to follow GPP guidelines in the design and implementation of DISCOVER, since GPP was developed partly as a response to the failure of previous prevention trials involving tenofovir."

Published
17 November 2016
From
HIV Prevention Justice Alliance
Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?

Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.

Published
17 November 2016
From
The Body
Statement on DISCOVER Study of F/TAF for PrEP

Gilead Sciences released this statement after considerable interest and concerns abut the forthcoming study of their new tenofovir formulation, TAF, for use in PrEP. The TAF/FTC pill is called Descovy(R). "Gilead Sciences is sponsoring a clinical trial, known as the DISCOVER study, to test whether a combination of emtricitabine and tenofovir alafenamide (F/TAF) is as safe and effective as Truvada® (emtricitabine and tenofovir disoproxil fumarate, F/TDF) at reducing the risk of HIV infection when used as pre-exposure prophylaxis (PrEP). F/TAF was recently approved for HIV treatment, but it is not yet known whether it is effective as PrEP...."

Published
16 November 2016
From
Gilead Sciences
Who’s afraid of Mr Trump?

Will billions of dollars in US aid be slashed or redirected under President Trump? For aid agency planners, only one thing about the Trump presidency is certain right now: uncertainty.

Published
15 November 2016
From
IRIN
Where hepatitis C rates are seven times the US average — and a cure is kept out of reach

With the opioid epidemic steamrolling through Appalachia, the new face of hepatitis C is increasingly young, white, and rural. In Kentucky, a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach.

Published
14 November 2016
From
STAT
In a Trump Presidency, Portents of Stigma and Sickness for People Living With HIV

Do not listen when someone tells you it will all be okay. It will not. For people living with HIV and those that advocate alongside them, a Trump White House coupled with a Republican-controlled Congress is nothing less than a waking nightmare.

Published
14 November 2016
From
The Body
The 13 NHS treatments at risk... because taxpayers face paying for controversial HIV drug

Hundreds of people with rare diseases could miss out on vital treatments after the NHS was ordered to consider bankrolling a controversial HIV pill.

Published
11 November 2016
From
Daily Mail
What the HIV/AIDS Community Is Saying About the 2016 Election Results

Trump did not mention HIV/AIDS in his campaign speeches and platform. What does this mean in terms of fighting the epidemic during the next four years? Below we compile a list of comments and press releases from HIV advocates and AIDS service organizations.

Published
10 November 2016
From
Poz
NHS England loses appeal – it must consider providing PrEP

At the Court of Appeal in London this morning, three judges confirmed that NHS England is responsible for providing PrEP. Key to the case is the fact

Published
10 November 2016
By
Roger Pebody
NHS England has power to fund Prep HIV drug, court decides

The Court of Appeal has ruled that the NHS in England has the power to fund a drug which prevents HIV infection in people at high risk of the virus. NHS England had previously said that local authorities should provide the pre-exposure prophylaxis drug - known as Prep - because they are responsible for preventative health. But councils insisted they had too little money. An estimated 14,000 people would be eligible for Prep in England. NHS England said the judgment confirmed that it had the ability, but not the obligation, to fund Prep.

Published
10 November 2016
From
BBC

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.